Diabetes Center at UCSF - Clinical Trial Volunteer Information

Diabetes Endocrinology Research Center (DERC)

DERC was established to support and enhance interactions among an outstanding team of investigators involved in Type 1 or 2 diabetes research.

UCSF JDRF CENTER (CCCT)

The mission of the center is to develop and test a new approach to the treatment of Type 1 diabetes by bringing together researchers from 5 academic institutions and 1 commercial partner.

Clinical Trial Volunteer Information

The Diabetes Center at UCSF typically conducts numerous clinical trials relating to the diagnosis, prevention and treatment of type 1 and type 2 diabetes. A list of studies that are currently recruiting is provided below for those who may be interested in volunteering in clinical studies. The goal of the intervention studies is to preserve insulin secretion in people recently diagnosed with the disease."

In the near future, we are planning to launch Diabetes Prevention Trials to determine whether new therapies can delay, or prevent, the onset of type 1 diabetes in "at risk" individuals.

If you are considering volunteering for a clinical trial, there are many things to think about. Understanding the basics of clinical trials and the process can help you make a more informed decision. The Diabetes Center recommends reading this short introduction to clinical trials before you decide to volunteer. The document also contains links to additional information and other online clinical trials information.

For more information on Diabetes Research, please contact Kathleen Fraser at 415/353-9084 or email kfraser@diabetes.ucsf.edu.

VOLUNTEERING FOR A CLINICAL TRIALS - Introduction

Clinical Trial

ALPHA LIPOIC ACID AND INSULIN RESISTANCE – NON DIABETICS NON DIABETICS: AGE 20 TO 50, NOT EXERCISING REGULARLY AND OF NORMAL BODY WEIGHT (Chromium)

Clinical Trial Type 1

NEW ONSET OF TYPE 1 DIABETES - AGE 12 TO 35 YEARS WITHIN 100 DAYS OF DIAGNOSIS - THYMOGLOBULIN NEW ONSET TYPE 1 DIABETES: AGE 16 TO 45 YEARS WITHIN 3 MONTHS OF DIAGNOSIS - GAD STUDY PEOPLE WITH TYPE I DIABETES: AGE 18 AND OLDER (ISLET CELL TRANSPLANTATION USING BELATACEPT)RECENT ONSET OF TYPE 1 DIABETES: AGE 8 TO 30 YEARS WITHIN 12 MONTHS OF DIAGNOSIS - TREATMENT OF TYPE 1 DIABETES MELLITUS WITH HOKT3Y1 (ALA-ALA - ANTI-CD3)RELATIVES OF PEOPLE WITH TYPE 1 DIABETES FROM AGE 3 TO AGE 45. AN ORAL INSULIN PREVENTATIVE STUDY.RECENT ONSET OF TYPE 1 DIABETES: AGE 16 TO 35 YEARS WITHIN 12 WEEKS OF DIAGNOSIS - TREATMENT OF TYPE 1 DIABETES MELLITUS WITH TEPLIZUMAB - HOKT3Y1 (ALA-ALA)RELATIVES OF TYPE 1 DIABETICS: AGE 1 TO 45 YEARS (Antibody Screening)MEXICAN-AMERICAN OR AFRICAN-AMERICAN FAMILIES WTIH TYPE 1 DIABETES RECENT ONSET TYPE 1 DIABETES AGE 18 AND OLDER WITHIN 12 MONTHS OF DIAGNOSIS. TCELL ASSAY STUDY

Clinical Trial Type 2

PEOPLE WITH TYPE 2 DIABETES: AGE 18 AND OLDER STUDY TO LOOK AT THE BONE DENSITY AND QUALITY AMONG POSTMENOPAUSAL WOMEN, 55-75 YEARS OLD WITH AND WITHOUT TYPE 2 DIABETES